Drug Profile

Research programme: anticancer T-cell therapies - BlueSphere Bio

Alternative Names: TCX-101

Latest Information Update: 28 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
No development reported Haematological malignancies

28 Aug 2023 No recent reports of development identified for research development in Haematological-malignancies in USA (Parenteral)
08 Apr 2022 BlueSphere Bio plans to file an IND application for Acute myeloid leukaemia, Acute lymphocytic leukaemia and Myelodysplastic syndrome by the end of 2022
19 Aug 2021 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) (BlueSphere Bio pipeline, August 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com